Clinical pharmacology of etoricoxib: a novel selective COX-2 inhibitor

被引:46
|
作者
Patrignani, P
Capone, ML
Tacconelli, S
机构
[1] Univ G dAnnunzio, Sch Med, Ctr Excellence Aging, I-66013 Chieti, Italy
[2] Univ G dAnnunzio, Sch Med, Div Pharmacol, Dept Med, I-66013 Chieti, Italy
关键词
acute gouty arthritis; acute pain; chronic law-back pain; chronic musculo-skeletal pain; COX-2; coxibs; etoricoxib; gastrointestinal toxicity; non-steroidal anti-inflammatory drugs; osteoarthritis; primary dysmenorrhoea; renal toxicity; rheumatoid arthritis;
D O I
10.1517/14656566.4.2.265
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The development of COX-2 inhibitors with improved biochemical selectivity (such as etoricoxib and valdecoxib) over that of commercially available coxibs has been driven by the potential advantage of safety using higher coxib doses for increased efficacy. Etoricoxib has been approved in the UK as a once-daily medicine for symptomatic relief in the treatment of osteoarthritis (OA), rheumatoid arthritis (RA) and acute gouty arthritis. It is currently approved with additional indications (i.e., for relief of acute pain associated with dental surgery, for primary dysmenorrhoea and for chronic musculo-skeletal pain, including chronic lower-back pain) in Mexico, Brazil and Peru. Etoricoxib has an in vitro COX-1/COX-2 IC50 ratio of 344, the highest of any coxib. The administration of therapeutic doses of etoricoxib to healthy subjects does not affect COX-1 activity in circulating platelets and gastric biopsies. The profound inhibition of monocyte COX-2 activity at 24 h after dosing, as predicted by a pharmacological half-life of similar to 22 h, supports a once-daily dosing regimen of etoricoxib. In randomised, well-controlled clinical trials, etoricoxib has been shown to have a comparable clinical efficacy with traditional NSAIDs. Combined analysis of efficacy trials with etoricoxib versus non-selective NSAIDs has shown that the drug halves both investigator-reported upper gastrointestinal perforation, ulcers and bleeds (PUBs) and confirmed PUBs, and reduces the need for gastroprotective agents and gastrointestinal comedications by similar to 40%. The risk of lower extremity oedema and hypertension adverse experiences with etoricoxib was low and generally similar to comparator NSAIDs in a combined analysis of eight Phase III studies in OA, RA, chronic low-back pain and surveillance endoscopy. Large, randomised clinical trials have been planned to confirm the renal, gastrointestinal and cardiovascular safety of etoricoxib.
引用
收藏
页码:265 / 284
页数:20
相关论文
共 50 条
  • [1] Characterization of etoricoxib, a novel, selective COX-2 inhibitor
    Dallob, A
    Hawkey, CJ
    Greenberg, H
    Wight, N
    De Schepper, P
    Waldman, S
    Wong, P
    DeTora, L
    Gertz, B
    Agrawal, N
    Wagner, J
    Gottesdiener, K
    JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (06): : 573 - 585
  • [2] Clinical pharmacology of the selective COX-2 inhibitor
    Burian, M
    Geisslinger, G
    ORTHOPADE, 2003, 32 (12): : 1078 - +
  • [3] Etoricoxib: A highly selective COX-2 inhibitor
    Martina, SD
    Vesta, KS
    Ripley, TL
    ANNALS OF PHARMACOTHERAPY, 2005, 39 (05) : 854 - 862
  • [4] Clinical pharmacology of celecoxib, a COX-2 selective inhibitor
    Antoniou, Katerina
    Malamas, Michael
    Drosos, Alexandros A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (11) : 1719 - 1732
  • [5] Etoricoxib, a selective COX-2 inhibitor, in primary dysmenorrhea
    Malmstrom, K
    Daniels, S
    McGratty, M
    Kotey, P
    Jacobsen, AR
    Desjardins, PJ
    OBSTETRICS AND GYNECOLOGY, 2004, 103 (04): : 59S - 59S
  • [6] Polymorphs and hydrates of Etoricoxib, a selective COX-2 inhibitor
    Grobelny, Pawel
    Mukherjee, Arijit
    Desiraju, Gautam R.
    CRYSTENGCOMM, 2012, 14 (18): : 5785 - 5794
  • [7] Clinical pharmacology of novel selective COX-2 inhibitors
    Tacconelli, S
    Capone, ML
    Patrignani, P
    CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (06) : 589 - 601
  • [8] A convenient synthesis of the key intermediate of selective COX-2 inhibitor Etoricoxib
    Tartaggia, Stefano
    Caporale, Andrea
    Fontana, Francesco
    Stabile, Paolo
    Castellin, Andrea
    De Lucchi, Ottorino
    RSC ADVANCES, 2013, 3 (40) : 18544 - 18549
  • [9] Clinical pharmacology of selective COX-2 inhibitors
    Capone, ML
    Tacconelli, S
    Sciulli, MG
    Patrignani, P
    INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2003, 16 (02) : 49 - 58
  • [10] Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective inhibitor etoricoxib
    Curtis, Sean P.
    Ko, Amy T.
    Bolognese, James A.
    Cavanaugh, Paul F., Jr.
    Reicin, Alise S.
    CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (12) : 2365 - 2374